Moebius Medical

Our goal is to leverage our liposome technological expertise, our proven experience in the development of drugs and medical devices, and our deep understanding of joint lubrication and cartilage regeneration to bring innovative products to market that answer unmet medical needs. We are differentiated by our years of expertise and demonstrated success in the development of both drugs and medical devices. We are currently recruiting patients with symptomatic knee osteoarthritis to participate in a large clinical trial to be carried out in the US, Denmark and Hong Kong. Moebius Medical is an innovative clinical-stage biotech company that leverages its proprietary liposomal technologies and related expertise for the development of novel products. We were founded in 2008 within the RAD Biomed Accelerator to commercialize a patent-protected liposomal technology licensed from the Hebrew University of Jerusalem, the Technion Institute and Hadassah Medical Center. On the manufacturing and analytical side, we benefit from our proven expertise in the development of liposomal technologies, including the challenging aseptic manufacturing processes and complex analytical methods associated with the testing of liposomal products. Moebius Medical is an innovative clinical-stage biotech company that leverages its proprietary liposomal technologies and related expertise in the development of novel products. Moebius’s scientific team, which drives our business, bring years of experience and leadership in liposome technology, process development, analytics, and CMC (Chemistry, Manufacturing & Controls), which is complemented by a deep understanding of joint lubrication and cartilage regeneration.